Human peripheral blood lymphocytes were stained with Mouse Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB356, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), ...read more
Mouse myeloma cell line NS0-derived recombinant human HVEM/TNFRSF14 Pro37-Val202 (Ser108Thr and Ala140Arg) Accession # AAB58354
Detects human HVEM/TNFRSF14 in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant human (rh) CD30 and no cross-reactivity with rh4-1BB, rhCD27, rhCD40, rhDR3, rhDR6, rhFas, rhGITR, rhNGF-R, rhOPG, rhRANK, recombinant mouse (rm) RANK, rhTAJ, rhTNF RI, rhTNF RII, or rmTNF RI is observed.
Protein A or G purified from ascites
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for HVEM/TNFRSF14 Antibody (94801) [Unconjugated]
Herpes virus entry mediator A
Herpesvirus entry mediator A
tumor necrosis factor receptor superfamily member 14
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entrymediator)
Tumor necrosis factor receptor-like 2
tumor necrosis factor receptor-like gene2
Herpesvirus entry mediator (HVEM), also referred to as TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. In the TNF superfamily nomenclature, HVEM is referred to as TNFRSF14. Human HVEM cDNA encodes a 283 amino acid (aa) protein with a probable 36 aa signal peptide, a 166 aa extracellular domain, a 23 aa transmembrane region and a 58 aa cytoplasmic region. The extracellular domain of HVEM contains several cysteine-rich repeats characteristic of TNF receptor superfamily members. The short cytoplasmic region lacks a death domain present in some TNF receptor family members, but contains a TRAF (TNF receptor-associated factor) interaction domain. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D. Two TNF superfamily ligands, including the secreted TNF‑ beta (lymphotoxin alpha ) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LT beta R, the receptor for lymphotoxin alpha beta heterotrimer.
Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
Mauri, D.N. et al. (1998) Immunity 8:21.
Montgomery, R.I. et al. (1996) Cell 87:427.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our HVEM/TNFRSF14 Antibody (94801) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.